|
DK1318997T3
(da)
*
|
2000-09-15 |
2006-09-25 |
Vertex Pharma |
Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
|
|
MXPA06005735A
(es)
*
|
2003-11-24 |
2006-08-17 |
Hoffmann La Roche |
Pirazolil e imidazolil pirimidinas.
|
|
WO2005100342A1
(en)
*
|
2004-03-26 |
2005-10-27 |
Vertex Pharmaceuticals, Incorporated |
Pyridine inhibitors of erk2 and uses thereof
|
|
RU2434871C2
(ru)
*
|
2005-02-03 |
2011-11-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы
|
|
NZ564065A
(en)
*
|
2005-05-20 |
2011-03-31 |
Vertex Pharma |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
JP5119154B2
(ja)
|
2005-09-22 |
2013-01-16 |
インサイト・コーポレイション |
Ｊａｎｕｓキナーゼの四環系阻害剤
|
|
AR058073A1
(es)
*
|
2005-10-03 |
2008-01-23 |
Astrazeneca Ab |
Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
|
|
US20080214560A1
(en)
*
|
2005-10-03 |
2008-09-04 |
Astrazeneca Ab |
Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
|
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス，インコーポレイティド |
Ｐｄｅ阻害による神経新生の調節
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
TWI630207B
(zh)
|
2005-12-13 |
2018-07-21 |
英塞特控股公司 |
作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
|
|
WO2007076474A1
(en)
*
|
2005-12-23 |
2007-07-05 |
Kalypsys, Inc. |
Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007111275A1
(ja)
*
|
2006-03-24 |
2007-10-04 |
The University Of Tokyo |
シグナル伝達阻害方法、それに用いるシグナル伝達阻害剤およびその用途
|
|
CN101460499A
(zh)
*
|
2006-04-05 |
2009-06-17 |
沃泰克斯药物股份有限公司 |
可用作janus激酶抑制剂的去氮杂嘌呤
|
|
AR060635A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
JP2010505811A
(ja)
|
2006-10-04 |
2010-02-25 |
ファイザー・プロダクツ・インク |
カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
ES2569528T3
(es)
|
2007-11-16 |
2016-05-11 |
Incyte Holdings Corporation |
4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
|
|
PL2288610T3
(pl)
|
2008-03-11 |
2017-12-29 |
Incyte Holdings Corporation |
Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
|
|
US8871753B2
(en)
|
2008-04-24 |
2014-10-28 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
GB2465405A
(en)
*
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US8178529B2
(en)
|
2009-04-15 |
2012-05-15 |
Astrazeneca Ab |
Imidazole substituted pyrimidines
|
|
EP3643312A1
(en)
|
2009-05-22 |
2020-04-29 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
CN105541847B
(zh)
|
2009-10-09 |
2019-08-16 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
|
EP3050882B1
(en)
|
2010-03-10 |
2018-01-31 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
SG10201503983QA
(en)
|
2010-05-21 |
2015-06-29 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
|
PT2597084T
(pt)
|
2010-07-08 |
2016-08-12 |
Kaken Pharma Co Ltd |
Derivado de n-hidroxiformamida e medicamento contendo o mesmo
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
WO2012117048A1
(en)
*
|
2011-03-02 |
2012-09-07 |
Lead Discovery Center Gmbh |
Pharmaceutically active disubstituted triazine derivatives
|
|
JP5947818B2
(ja)
|
2011-03-02 |
2016-07-06 |
リード ディスカバリー センター ゲーエムベーハー |
薬学的活性化二置換ピリジン誘導体
|
|
CA2833288A1
(en)
|
2011-04-19 |
2012-10-26 |
Bayer Intellectual Property Gmbh |
Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
|
|
TWI555737B
(zh)
|
2011-05-24 |
2016-11-01 |
拜耳知識產權公司 |
含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
|
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
JP5976814B2
(ja)
|
2011-09-16 |
2016-08-24 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
|
|
EP2755956B1
(en)
|
2011-09-16 |
2016-05-18 |
Bayer Intellectual Property GmbH |
2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
|
|
IN2014KN02601A
(enExample)
|
2012-04-24 |
2015-05-08 |
Vertex Pharma |
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
WO2014019908A2
(en)
*
|
2012-08-02 |
2014-02-06 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrroles active as kinases inhibitors
|
|
ES2595222T3
(es)
|
2012-10-18 |
2016-12-28 |
Bayer Pharma Aktiengesellschaft |
Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
|
|
CA2888381A1
(en)
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
|
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
|
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
|
SMT202100687T1
(it)
|
2013-03-12 |
2022-01-10 |
Vertex Pharma |
Inibitori della dna-pk
|
|
WO2014154723A1
(en)
*
|
2013-03-29 |
2014-10-02 |
F. Hoffmann-La Roche Ag |
Novel pyrrole derivatives for the treatment of cancer
|
|
SG10201912203XA
(en)
|
2013-08-07 |
2020-02-27 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
ES2705342T3
(es)
|
2013-10-17 |
2019-03-22 |
Vertex Pharma |
Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
EP3207037B1
(en)
|
2014-10-16 |
2019-01-23 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
|
|
WO2016150902A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
|
|
WO2016150903A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
|
|
WO2016150893A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
|
|
EP3356373B1
(en)
|
2015-09-29 |
2020-02-19 |
Bayer Pharma Aktiengesellschaft |
Novel macrocyclic sulfondiimine compounds
|
|
CN108368129B
(zh)
|
2015-10-08 |
2021-08-17 |
拜耳医药股份有限公司 |
改性大环化合物
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
WO2018177889A1
(en)
|
2017-03-28 |
2018-10-04 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|
|
ES2900199T3
(es)
|
2017-03-28 |
2022-03-16 |
Bayer Ag |
Novedosos compuestos macrocíclicos inhibidores de PTEFB
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
EP3746429B1
(en)
|
2018-01-30 |
2022-03-09 |
Incyte Corporation |
Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
CN111727183B
(zh)
|
2018-02-13 |
2023-12-29 |
拜耳公司 |
5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途
|
|
PT3773593T
(pt)
|
2018-03-30 |
2024-06-25 |
Incyte Corp |
Tratamento da hidradenite supurativa com inibidores de jak
|
|
CN112955214B
(zh)
|
2018-10-29 |
2024-05-07 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
JP7717065B2
(ja)
|
2019-11-22 |
2025-08-01 |
インサイト コーポレーション |
Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN113288899B
(zh)
*
|
2021-05-17 |
2022-10-11 |
浙江工业大学 |
一种杂环硫醇类化合物在制备抗肿瘤药物中的应用
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|